Pathogen inactivation in labile blood products;Évolution des techniques de préparation des produits sanguins labiles (PSL) : inactivation des pathogènes dans les PSL

Transfusion Clinique et Biologique

Volumn 16, Issue 2, 2009, Pages 179-189

  Naegelen, C ^a   Isola, H ^a   Dernis, D ^a   Maurel, J P ^a   Tardivel, R ^a   Bois, S ^a   Vignoli, C ^a   Cazenave, J P ^a  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Attenuation; Inactivation; Labile blood products; Pathogens; Transfusion safety

Indexed keywords

AMOTOSALEN; ARGININE; DETERGENT; GLUCONATE CALCIUM; LYSINE; METHYLENE BLUE; MIRASOL; NONOXINOL 9; RIBOFLAVIN; SORBITOL; SUCROSE; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG;

BLOOD STORAGE; BLOOD TRANSFUSION; CHEMICAL ANALYSIS; DISEASE TRANSMISSION; DRUG EFFICACY; FRANCE; HUMAN; INFECTION RISK; LABORATORY TEST; MICROORGANISM DETECTION; PHOTOCHEMISTRY; QUALITY CONTROL; RISK FACTOR; SAFETY; SHORT SURVEY; ULTRAVIOLET A RADIATION; ULTRAVIOLET C RADIATION; ULTRAVIOLET RADIATION; VIRUS ATTENUATION; ARTICLE; BLOOD BANK; BLOODBORNE BACTERIUM; HEAT; METHODOLOGY; MICROBIOLOGY; PLASMA; THROMBOCYTE; VIRUS INACTIVATION;

BLOOD BANKS; BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; HOT TEMPERATURE; HUMANS; METHYLENE BLUE; PHOTOCHEMICAL PROCESSES; PLASMA; QUALITY CONTROL; SAFETY; ULTRAVIOLET RAYS; VIRUS INACTIVATION;

EID: 66049132844     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2009.03.022     Document Type: Short Survey

References (56)

1. Webert K.E., Cserti C.M., Hannon J., Lin Y., Pavenski K., Pendergrast J.M., et al. Proceedings of a Consensus Conference : pathogen inactivation-making decisions about new technologies. Transfus Med Rev 22 (2008) 1-34
2. McCullough J. Pathogen inactivation: a new paradigm for blood safety. Transfusion 47 (2007) 2180-2184
3. Klein H.G., Anderson D., Bernardi M.J., Cable R., Carey W., Hoch J.S., et al. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 47 (2007) 2338-2347
4. Wu Y.Y., and Snyder E.L. Safety of the blood supply: role of pathogen reduction. Blood Rev 17 (2003) 111-122
5. Alter H.J., and Klein H.G. The hazards of blood transfusion in historical perspective. Blood 112 (2008) 2617-2626
6. Surveillance épidémiologique des donneurs de sang en France 1992-2007, INVS, INTS, EFS, Service de santé des armées.
7. Rapport d'activité 2007, Pôle vigilances, Direction médicale, Établissement français du sang.
8. Rapport Hémovigilance 2006, Afssaps.
9. Friedman L.I., Stromberg R.R., and Wagner S.J. Reducing the infectivity of blood components. What we have learned. Immunol Invest 24 (1995) 49-71
10. Adler S.P., Lawrence L.T., Bagget J., Biro V., and Sharp D.E. Prevention of transfusion associated cytomegalovirus infection in very low-birthweight infants using frozen blood and donors sero-negative for cytomegalovirus. Transfusion 24 (1984) 333-335
11. Andreu G., Marinière A.M., Fretz C., Emile J.F., le groupe CMV de la SNTS, Bierling P., et al. Infections à cytomégalovirus post-transfusionnelles : incidence et moyens de prévention. Rev Fr Transfus Hemobiol 34 (1991) 213-232
12. Bowden R.A., Slichter S.J., Sayers M., Weisdorf D., Cays M., Schoch G., et al. A comparison of filtered leukocyte reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion associated CMV infection after marrow transplant. Blood 86 (1995) 3598-3603
13. Kobayashi M., Yang M., Won K.W., Takahashi T.A., Ikeda H., and Sekiguchi S. Leukocyte depletion of HTLV-1 carrier red cell concentrates by filters. In: Sekiguchi S. (Ed). Clinical application of leukocyte depletion (1993), Blackwell Scientific, Boston 138-148
14. Qu L., Xu S.S., Rowe D.T., and Triulzi D.J. Efficacy of Epstein-Barr virus removal by leukoreduction of red blood cells. Transfusion 45 (2005) 591-595
15. Kitchen A.D., Mann G.F., Harrison J.F., and Zuckerman A.J. Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins. Vox Sang 56 (1989) 223-229
16. Prodouz K.N., Fratantoni J.C., Boone E.J., and Bonner R.F. Use of laser-UV for inactivation of virus in blood products. Blood 70 (1987) 589-592
17. Tolksdorf F., Walker W.H., Mohr H., Gravemann U., and Mueller T.H. Pathogen reduction in platelet concentrates using UVC light in combination with strong agitation: effect on activation markers and storage stability. AABB Annual Meeting (2007), Anaheim, USA
18. Terpstra Fokke G., Van't Wout A.B., Schuitemaker H., Van Engelenburg F., Dekkers D.W.C., Verhaar R., et al. Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates. Transfusion 48 (2008) 304-313
19. Lin L., Dikeman R., Molini B., Lukehart S.A., Lane R., Dupuis K., et al. Photochemical treatment of platelet concentrates with Amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 44 (2004) 1496-1504
20. Lin L., Hanson C.V., Alter H.J., Jauvin V., Bernard K.A., Murthy K.K., et al. Inactivation of viruses in platelet concentrates by photochemical treatment with Amotosalen and long-wavelength ultraviolet light. Transfusion 45 (2005) 580-590
21. Pinna D., Sampson-Johannes A., Clementi M., Poli G., Rossini S., Lin L., et al. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med 15 (2005) 269-276
22. Eastman R.T., Barrett L.K., Dupuis K., Buckner F.S., and Van Voorhis W.C. Leishmania inactivation in human pheresis platelets by a psoralen (Amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion 45 (2005) 1459-1463
23. Wesley C., Van Voorhis, Barrett L.K., Eastman R.T., et al. Trypanosoma cruzi Inactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV. Antimicrob Agents Chemother 47 (2003) 475-479
24. Singh Y., Sawyer L.S., Pinkoski L., Dupuis K.W., Hsu J., Lin L., et al. Photochemical treatment of plasma with Amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 46 (2006) 1168-1177
25. Sawyer L., Hanson D., Castro G., Luckett W., Dubensky Jr. T.W., and Stassinopoulos A. Inactivation of parvovirus B19 in human platelet concentrates by treatment with Amotosalen and ultraviolet A illumination. Transfusion 47 (2007) 1062-1070
26. Lam S., Tan H.C., Tan L.K., Ng L.C., Teo D., and Koh M. Efficacy of INTERCEPT Treatment for the Inactivation of Dengue Virus in Single-Donor Platelet Concentrate. Transfusion 47 (2007) 134A
27. Grellier P., Benach J., Labaied M., Charneau S., Gil H., Monsalve G., et al. Photochemical inactivation with Amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion 48 (2008) 1676-1684
28. Sawyer L., Dupuis K., and Sampson-Johannes A. Inactivation of Influenza A H5N1 and Lymphocytic Choriomeningitis Virus by the INTERCEPT Blood System (IBS). Transfusion 48 2S (2008) 88A
29. Goodrich R.P., Edrich R.A., Li J., and Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 35 (2006) 5-17
30. Ruane P.H., Edrich R., Gampp D., Keil S.D., Leonard R.L., and Goodrich R.P. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 44 (2004) 877-885
31. Li J., de Korte D., Woolum M.D., Ruane P.H., Keil S.D., Lockerbie O., et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 87 (2004) 82-90
32. Cardo L.J., Rentas F.J., Ketchum L., Salata J., Harman R., Melvin W., et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 90 (2006) 85-91
33. Cardo L.J., Salata J., Mendez J., Reddy H., and Goodrich R. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 37 (2007) 131-137
34. Rentas F., Harman R., Gomez C., Salata J., Childs J., Silva T., et al. Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model. Transfusion 47 (2007) 240-247
35. Williamson L.M., Cardigan R., and Prowse C.V. Methylene blue-treated fresh frozen plasma: whath is its the contribution to blood safety?. Transfusion 43 (2003) 1322-1329
36. Aznar J.A., Bonanad S., Montoro J.M., Hurtado C., Cid A.R., Soler M.A., et al. Influence of methylene blue photoinactivation treatment on coagulation factors from Fresh Frozen Plasma, cryoprecipitates and cryosupernatants. Vox Sang 79 (2000) 156-160
37. Lambrecht B., Mohr H., Knüver-Hopf J., and Schmitt H. Photoinactivation of viruses in human Fresh Frozen Plasma by phenothiazine dyes in combination with visible light. Vox Sang 60 (1991) 207-213
38. Mohr H., Knüver-Hopf J., Lambrecht B., Scheidecker H., and Schmitt H. No evidence for neoantigens in human plasma after photochemical virus inactivation. Ann Hematol 65 (1992) 224-228
39. Zeiler T., Riess H., Wittman G., Hintz G., Zimmermenn R., Müller C., et al. The effect of methylene blue-phototreatment on plasma proteins and in vitro coagulation capability of single-donor Fresh Frozen Plasma. Transfusion 34 (1994) 685-689
40. Aznar J.A., Molina R., and Montoro J.M. Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasm. Transfusion 39 (1999) 748-750
41. Riggert J., Humpe A., Legler T.J., Wolf C., Simson G., and Köhler M. Filtration of methylene blue-photooxidized plasma: influence on coagulation and cellular contamination. Transfusion 41 (2001) 82-86
42. Castro E., Barea L., Gonzalez R., and Bueno J.L. Impact of quarantine and methylene blue/light treatment on plasma quality. Transfusion 38 Suppl (1998) S86
43. Castrillo A., Eiras A., Casro A., Areal C., Adelantado M., Cid J., et al. Evaluation of methylene blue treated plasma. Vox Sang 78 Suppl 1 (2000) P545
44. Hornsey V., Dummond O., Young D., Docherty A., and Prowse C. A potential improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-tronic system. Vox Sang 78 Suppl 1 (2000) P538
45. Verpoort T., Chollet S., Lebrun F., Goudalier F., Mohr H., and Walker W.H. Elimination of methylene blue from photo-dynamically treated virus inactivated fresh-frozen plasma: the Bluflex filter. Transfus Clin Biol 8 Suppl 1 (2001) P147
46. Seghatchian J., and Krailadsiri P. What's happening: the quality of methylene blue treated. Transfus Apher Sci 25 (2001) 227-231
47. Castrillo A., Eiras A., Castro A., Adelantado M., Areal C., Cid J., et al. A new evaluation of methylene blue treated plasma. Transfus Clin Biol 8 Suppl. 1 (2001) 103S
48. Yarranton H., Lawrie A.S., Purdy G., Mackie I.J., and Machin S.J. Comparison of von Willebrand factor antigen, von Willebrand factor-cleacing protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 14 (2004) 39-44
49. Solheim G., and Seghatchian J. The six questions of pathogen reduction technology: An overview of current opinions. Transfus Apher Sci 39 (2008) 51-57
50. Solheim G. Pathogen reduction of blood components. Transfus Apher Sci 39 (2008) 75-82
51. Osselaer J.C., Debry C., Goffaux M., Pineau J., Calomme G., Dubuc E., et al. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and Amotosalen. Transfusion 48 (2008) 108-117
52. Isola H, Kientz D, Wiesel M-L, Lin L, Mayaudon V, Cazenave J-P, et al. In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set. Vox Sang 2006;90:128-30.
53. Cazenave J.P., Aleil B., Wiesel M.L., Laforêt M., and Isola H. In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using Amotosalen. Vox Sang 86 (2004) 201-202
54. Picker S.M., Speer R., and Gathof B.S. Functional characteristics of buffy-coat PLTs photochemically treated with Amotosalen-HCl for pathogen inactivation. Transfusion 44 (2004) 320-329
55. Janetzko K., Lin L., Eichler H., Mayaudon V., Flament J., and Klüter H. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 86 (2004) 239-245
56. Jansen G.A., van Vliet H.H., Vermeij H., Beckers E.A., Leebeek F.W., Sonneveld P., et al. Functional characteristics of photochemically treated platelets. Transfusion 44 (2004) 313-319